Literature DB >> 15472110

Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion.

José Alvarez-Sabín1, Carlos A Molina, Marc Ribó, Juan F Arenillas, Joan Montaner, Rafael Huertas, Esteban Santamarina, Marta Rubiera.   

Abstract

BACKGROUND AND
PURPOSE: We evaluated the impact of admission hyperglycemia (HG) on stroke outcome in relation to the timing of reperfusion in patients treated with tissue plasminogen activator (tPA).
METHODS: We studied 138 consecutive stroke patients with a documented middle cerebral artery (MCA) occlusion treated with intravenous tPA <3 hours of stroke onset. Serum glucose was determined at baseline before tPA administration. HG was defined as a glucose level >140 mg/dL. National Institutes of Health Stroke Scale (NIHSS) scores were obtained at baseline and 24 hour. Transcranial Doppler monitoring of recanalization was conducted during the first 12 hour of stroke onset. mRS was used to assess outcome at 3 months.
RESULTS: Median baseline NIHSS score was 17 points. At baseline, 42 (37.3%) patients were hyperglycemic and 96 (62.7%) normoglycemic. Reperfusion was achieved <3 hours of stroke onset in 32 (23%) patients, between 3 to 6 hours in 49 (36%), 6 to 12 hours in 15 (12%), and in 32 (23%) the MCA remained occluded at 12 hours. A logistic regression model revealed that baseline NIHSS score >16 points (odds ratio [OR], 3.32; 95% CI, 2.18 to 24.7; P=0.032) and admission glucose level >140 mg/dL (OR, 5.65; 95% CI, 1.97 to 16.18; P=0.002) independently predicted poor outcome (modified Rankin scale, 3 to 6) at 3 months. After adjusting by age, stroke severity, site of MCA occlusion, and degree of recanalization, the contribution of HG for poor outcome was higher as shorter the time to reperfusion. The highest odds for poor outcome related to HG corresponded to patients who recanalized <3 hour (OR, 3.1; 95% CI, 1.8 to 14.3; P=0.002), as compared with those who recanalized between 3 and 6 hours (OR, 2.1; 95% CI, 1.1 to 16; P=0.034) and between 6 to 12 hours (OR, 1.1; 95% CI, 0.7 to 21; P=0.43). Moreover, baseline glucose level was negatively correlated (r=-0.45; P=0.001) with the degree of improvement in the NIHSS score at 24 hours after early (<3 hours) but not after delayed (>3 hours) or no recanalization.
CONCLUSIONS: The impact of admission HG on stroke outcome varies depending on the time to tPA-induced reperfusion. The detrimental effect of acute HG is higher after early than after delayed or no reperfusion. Ultra-early glycemic control before reperfusion may improve the efficacy of thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472110     DOI: 10.1161/01.STR.0000143728.45516.c6

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  41 in total

1.  Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator.

Authors:  William J Meurer; Phillip A Scott; Angela F Caveney; Jennifer J Majersik; Shirley M Frederiksen; Annette Sandretto; Ann B Holden; Robert Silbergleit
Journal:  Int J Stroke       Date:  2010-06       Impact factor: 5.266

2.  Predicting discharge mortality after acute ischemic stroke using balanced data.

Authors:  King Chung Ho; William Speier; Suzie El-Saden; David S Liebeskind; Jeffery L Saver; Alex A T Bui; Corey W Arnold
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

Review 3.  Mechanical interventions to treat acute stroke.

Authors:  David Fussell; H Christian Schumacher; Philip M Meyers; Randall T Higashida
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 4.  Diabetes, adult neurogenesis and brain remodeling: New insights from rodent and zebrafish models.

Authors:  Anne-Claire Dorsemans; David Couret; Anaïs Hoarau; Olivier Meilhac; Christian Lefebvre d'Hellencourt; Nicolas Diotel
Journal:  Neurogenesis (Austin)       Date:  2017-01-31

5.  Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.

Authors:  Xiang Fan; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

Review 6.  Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).

Authors:  David S Liebeskind
Journal:  Stroke       Date:  2009-07-16       Impact factor: 7.914

7.  Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment.

Authors:  Adnan I Qureshi; Haitham M Hussein; Mohamed Abdelmoula; Alexandros L Georgiadis; Nazli Janjua
Journal:  Neurocrit Care       Date:  2008-12-03       Impact factor: 3.210

8.  Intensive perioperative glucose control does not improve outcomes of patients submitted to open-heart surgery: a randomized controlled trial.

Authors:  Raquel Pei Chen Chan; Filomena Regina Barbosa Gomes Galas; Ludhmila Abrahão Hajjar; Carmen Narvaes Bello; Marilde Albuquerque Piccioni; José Otávio Costa Auler
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  Early changes in physiological variables after stroke.

Authors:  Andrew A Wong; Stephen J Read
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

10.  Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia.

Authors:  Weiguo Li; Roshini Prakash; Aisha I Kelly-Cobbs; Safia Ogbi; Anna Kozak; Azza B El-Remessy; Derek A Schreihofer; Susan C Fagan; Adviye Ergul
Journal:  Diabetes       Date:  2009-10-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.